Should I buy or sell Lucid Diagnostics stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Lucid Diagnostics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" LUCD shares. View LUCD analyst ratings or view top-rated stocks .

What is Lucid Diagnostics' stock price target for 2024?

2 brokers have issued 1-year price targets for Lucid Diagnostics' stock. Their LUCD share price targets range from $2.50 to $4.00. On average, they expect the company's stock price to reach $3.25 in the next twelve months. This suggests a possible upside of 111.0% from the stock's current price. View analysts price targets for LUCD or view top-rated stocks among Wall Street analysts .

How have LUCD shares performed in 2023?

Lucid Diagnostics' stock was trading at $1.36 on January 1st, 2023. Since then, LUCD shares have increased by 13.2% and is now trading at $1.54. View the best growth stocks for 2023 here .

When is Lucid Diagnostics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 12th 2024. View our LUCD earnings forecast .

How were Lucid Diagnostics' earnings last quarter?

Lucid Diagnostics Inc. (NASDAQ:LUCD) announced its earnings results on Monday, March, 28th. The company reported ($0.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by $0.12. Lucid Diagnostics had a negative trailing twelve-month return on equity of 901.79% and a negative net margin of 4,153.13%.

When did Lucid Diagnostics IPO?

(LUCD) raised $75 million in an initial public offering on Thursday, October 14th 2021. The company issued 5,000,000 shares at $14.00-$16.00 per share.

Who are Lucid Diagnostics' major shareholders?

Lucid Diagnostics' stock is owned by many different institutional and retail investors. Top institutional investors include LPL Financial LLC (0.07%). View institutional ownership trends .

How do I buy shares of Lucid Diagnostics?

Shares of LUCD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Positive News SentimentPositive News

Lucid Diagnostics Stock Price, News & Analysis (NASDAQ:LUCD)

$1.54

+0.07 (+4.76%)

(As of 12/4/2023 ET)

Compare

Today's Range: $1.47
▼
$1.54
50-Day Range: $1.16
▼
$1.54
52-Week Range: $1.04
▼
$2.00

Volume: 74,103 shs
Average Volume: 64,765 shs
Market Capitalization: $68.79 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $3.25

Lucid Diagnostics MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 111.0% Upside
$3.25 Price Target
Short Interest: Healthy
1.17% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: Selling Shares
$5,821 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($1.26) to ($0.89) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.03 out of 5 stars

Medical Sector

569th out of 952 stocks

Surgical & Medical Instruments Industry

62nd out of 89 stocks

3.5

Analyst's Opinion

Consensus Rating
Lucid Diagnostics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $3.25, Lucid Diagnostics has a forecasted upside of 111.0% from its current price of $1.54.
Amount of Analyst Coverage
Lucid Diagnostics has only been the subject of 2 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
1.17% of the float of Lucid Diagnostics has been sold short.
Short Interest Ratio / Days to Cover
Lucid Diagnostics has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Lucid Diagnostics has recently increased by 9.57%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Lucid Diagnostics does not currently pay a dividend.
Dividend Growth
Lucid Diagnostics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for LUCD.

2.7

News and Social Media Coverage

News Sentiment
Lucid Diagnostics has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.76 average news sentiment score of Medical companies.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Lucid Diagnostics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $5,821.00 in company stock.
Percentage Held by Insiders
Only 4.80% of the stock of Lucid Diagnostics is held by insiders.
Percentage Held by Institutions
Only 4.30% of the stock of Lucid Diagnostics is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Lucid Diagnostics are expected to grow in the coming year, from ($1.26) to ($0.89) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Lucid Diagnostics is -1.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Lucid Diagnostics is -1.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Lucid Diagnostics has a P/B Ratio of 2.61. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Lucid Diagnostics Stock (NASDAQ:LUCD)

Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. The company focuses on patients with gastroesophageal reflux disease who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma (EAC). It offers EsoCheck, a cell collection device to prevent EAC deaths; and EsoGuard, an Esophageal DNA Test. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.

LUCD Stock Price History

30 days | 90 days | 365 days | Advanced Chart

LUCD Stock News Headlines

November 16, 2023 | finance.yahoo.com

Lucid Diagnostics Inc. (NASDAQ:LUCD) Q3 2023 Earnings Call Transcript

November 14, 2023 | msn.com

Lucid Diagnostics Non-GAAP EPS of -$0.22 in-line, revenue of $0.8M beats by $0.01M

December 5, 2023 | Wealthpress (Ad)

Trading Experts Call It “The Perfect Tesla Trade”

Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.

November 10, 2023 | benzinga.com

Earnings Preview For Lucid Diagnostics

November 9, 2023 | msn.com

Elucid closes $80m Series C for AI cardiovascular risk diagnostic tool

November 2, 2023 | finance.yahoo.com

Lucid Diagnostics to Present at Canaccord Genuity Medtech, Diagnostics, and Digital Health & Services Forum

November 1, 2023 | finance.yahoo.com

PAVmed to Hold a Business Update Conference Call and Webcast on November 15, 2023

October 31, 2023 | finance.yahoo.com

Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on November 14, 2023

December 5, 2023 | Wealthpress (Ad)

Trading Experts Call It “The Perfect Tesla Trade”

October 31, 2023 | finance.yahoo.com

Lucid Diagnostics Announces PREVENT and PREVENT-FF Registries of EsoGuard® Esophageal Precancer Detection

September 21, 2023 | finance.yahoo.com

PAVmed and Lucid Diagnostics to Participate in Panel Presentation at the 2023 Cantor Fitzgerald Global Healthcare Conference

September 11, 2023 | cnbc.com

U.S. electric carmaker Lucid is exploring China entry; confirms mass market models ahead

August 24, 2023 | finance.yahoo.com

Lucid Diagnostics Executes First Direct Employer Contract to Provide EsoGuard® Esophageal Precancer Testing as an Employee Benefit

August 16, 2023 | finanznachrichten.de

PAVmed Inc.: PAVmed Provides Business Update and Second Quarter Financial Results

August 16, 2023 | finance.yahoo.com

Q2 2023 Lucid Diagnostics Inc Earnings Call

August 15, 2023 | finance.yahoo.com

PAVmed Provides Business Update and Second Quarter Financial Results

August 12, 2023 | businessinsider.com

I drove the $180,000 Lucid Air and saw why it's one of the most impressive Tesla rivals yet

July 31, 2023 | finance.yahoo.com

Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on August 15, 2023

July 31, 2023 | finance.yahoo.com

PAVmed to Hold a Business Update Conference Call and Webcast on August 16, 2023

July 29, 2023 | thestreet.com

Lucid Diagnostics Inc.

July 19, 2023 | finance.yahoo.com

PAVmed and Lucid Chairman and Chief Executive Officer, Dr. Lishan Aklog, Testifies at U.S. House of Representatives Energy and Commerce Committee, Hearing on Life-Saving Innovations and Medicare Coverage

June 22, 2023 | marketwatch.com

8-K: Lucid Diagnostics Inc.

June 14, 2023 | finance.yahoo.com

PAVmed to Participate in Healthcare Virtual Conference Presented by Maxim Group LLC

June 5, 2023 | finance.yahoo.com

Lucid Diagnostics Launches First EsoGuard® Mobile Test Unit

June 2, 2023 | finance.yahoo.com

PAVmed Digital Health Subsidiary, Veris Health, Joins Cancer Moonshot's CancerX Partnership as Founding Member

May 18, 2023 | finance.yahoo.com

Q1 2023 PAVmed Inc Earnings Call

May 17, 2023 | markets.businessinsider.com

Where Lucid Diagnostics Stands With Analysts

See More Headlines

Receive LUCD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lucid Diagnostics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/28/2022
Today: 12/04/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 3/12/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Surgical & medical instruments
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:LUCD
CUSIP: N/A
CIK: 1799011
Web: www.luciddx.com
Phone: 212-949-4319
Fax: N/A
Employees: 2,021
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $3.25
High Stock Price Target: $4.00
Low Stock Price Target: $2.50
Potential Upside/Downside: +111.0%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.30)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-56,170,000.00
Net Margins: -4,153.13%
Pretax Margin: -3,784.27%
Return on Equity: -901.79%
Return on Assets: -141.57%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.90
Quick Ratio: 0.90

Sales & Book Value

Annual Sales: $380,000.00
Price / Sales: 181.03
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.59 per share
Price / Book: 2.61

Miscellaneous

Outstanding Shares: 44,670,000
Free Float: 42,523,000
Market Cap: $68.79 million
Optionable: Not Optionable
Beta: 1.86

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

Dr. Lishan Aklog M.D. (Age 57)
Chairman & CEO
Dr. Sanford D. Markowitz M.D.
Ph.D., Cofounder & Strategic Advisor, Member of the Medical Advisor Board
Dr. Joseph Willis M.D.
Cofounder, Strategic Advisor & Member of Medical Advisory Board
Dr. Amitabh Chak M.D.
Cofounder, Strategic Advisor & Member of Medical Advisory Board
Richard D. Yazbeck
Chief Technology Officer
Dr. Suman M. Verma M.D.
Ph.D., Chief Scientific Officer
Dr. Brian J. deGuzman M.D. (Age 58)
Chief Compliance Officer
Mr. Michael Adam Gordon (Age 49)
General Counsel & Secretary
Michael Parks
Vice President of Investor Relations

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

LUCD Stock Analysis - Frequently Asked Questions

Should I buy or sell Lucid Diagnostics stock right now?: 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Lucid Diagnostics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" LUCD shares.
View LUCD analyst ratings or view top-rated stocks.
What is Lucid Diagnostics' stock price target for 2024?: 2 brokers have issued 1-year price targets for Lucid Diagnostics' stock. Their LUCD share price targets range from $2.50 to $4.00. On average, they expect the company's stock price to reach $3.25 in the next twelve months. This suggests a possible upside of 111.0% from the stock's current price.
View analysts price targets for LUCD or view top-rated stocks among Wall Street analysts.
How have LUCD shares performed in 2023?: Lucid Diagnostics' stock was trading at $1.36 on January 1st, 2023. Since then, LUCD shares have increased by 13.2% and is now trading at $1.54.
View the best growth stocks for 2023 here.
When is Lucid Diagnostics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 12th 2024.
View our LUCD earnings forecast.

How were Lucid Diagnostics' earnings last quarter?: Lucid Diagnostics Inc. (NASDAQ:LUCD) announced its earnings results on Monday, March, 28th. The company reported ($0.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by $0.12. Lucid Diagnostics had a negative trailing twelve-month return on equity of 901.79% and a negative net margin of 4,153.13%.
When did Lucid Diagnostics IPO?: (LUCD) raised $75 million in an initial public offering on Thursday, October 14th 2021. The company issued 5,000,000 shares at $14.00-$16.00 per share.
Who are Lucid Diagnostics' major shareholders?: Lucid Diagnostics' stock is owned by many different institutional and retail investors. Top institutional investors include LPL Financial LLC (0.07%).
View institutional ownership trends.
How do I buy shares of Lucid Diagnostics?: Shares of LUCD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:LUCD) was last updated on 12/5/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial